Clinic
First Step Pediatric Associates, P.A.
First Step Pediatric Associates, P.A. was paid $8.94M by Medicaid between Jan 2018 and Dec 2024, across 89 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 26% of everything it billed.
33Billing provider infoFIRST STEP PEDIATRIC ASSOCIATES, P.A.
CLEBURNE, TX 76033
CLEBURNE, TX 76033
33aNPI1669793758assigned 06/13/2010
33bProvider typePrimary Care Clinic/Center
28Total paid$8.94M
24GClaims366,742
24DCodes billed89
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in Texas
Rank by total paid#1 of 180
Median peer was paid$25K
This provider vs. median355×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 901 | $19K | |
| 2019 | 1,533 | $32K | |
| 2020 | 18,003 | $396K | |
| 2021 | 91,249 | $2.14M | |
| 2022 | 99,076 | $2.28M | |
| 2023 | 86,268 | $2.19M | |
| 2024incomplete | 69,712 | $1.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 26% | 66,690 | 55,644 | $2.34M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 28,063 | 25,733 | $1.39M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8.5% | 9,851 | 9,733 | $764K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 7.4% | 8,799 | 8,632 | $666K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.3% | 6,871 | 6,762 | $564K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 5.8% | 49,490 | 18,549 | $518K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.3% | 4,432 | 4,313 | $386K |
| 99429 | 3.7% | 10,446 | 10,311 | $333K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 2.9% | 6,650 | 6,381 | $258K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.4% | 16,491 | 15,614 | $218K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.2% | 11,613 | 7,303 | $199K |
| 99381 | 1.7% | 2,452 | 2,367 | $154K |
77 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.1% | 12,651 | $101K |
| 87428 | 1.0% | 1,284 | $89K | |
| 69210 | <1% | 2,217 | $81K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,025 | $79K |
| 99442 | <1% | 2,085 | $75K | |
| 90461 | <1% | 19,573 | $70K | |
| 87807 | <1% | 5,639 | $59K | |
| 17110 | <1% | 692 | $58K | |
| 94010 | <1% | 2,009 | $48K | |
| 99383 | <1% | 510 | $44K | |
| 87634 | <1% | 765 | $44K | |
| 92551 | <1% | 7,121 | $42K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,046 | $38K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 477 | $38K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 634 | $35K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,371 | $32K |
| 99382 | <1% | 292 | $25K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,668 | $24K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 459 | $22K |
| 99000 | <1% | 1,866 | $19K | |
| 88720 | <1% | 4,913 | $17K | |
| 99050 | <1% | 1,058 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,307 | $14K |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 1,020 | $13K |
| 99384 | <1% | 114 | $10K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 90 | $7K |
| 96160 | <1% | 4,154 | $7K | |
| 81002 | <1% | 2,448 | $7K | |
| 82947 | <1% | 1,691 | $5K | |
| 99441 | <1% | 209 | $5K | |
| 85018 | <1% | 2,874 | $5K | |
| 93000 | <1% | 275 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 77 | $2K |
| 92558 | <1% | 301 | $2K | |
| 80061 | Lipid panel | <1% | 172 | $2K |
| 86308 | <1% | 246 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 914 | $876.27 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 27 | $344.83 |
| 69209 | <1% | 27 | $339.66 | |
| 81025 | <1% | 50 | $333.70 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,790 | $242.57 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 16 | $209.44 |
| 99406 | <1% | 1,253 | $96.72 | |
| 83655 | <1% | 14 | $50.85 | |
| 99072 | <1% | 3,279 | $44.40 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 93 | $23.94 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 22 | $18.24 |
| 90677 | <1% | 1,508 | $1.85 | |
| 90662 | <1% | 161 | $1.03 | |
| 90661 | <1% | 38 | $0.06 | |
| 90620 | <1% | 514 | $0.02 | |
| 90686 | <1% | 2,805 | $0.02 | |
| 90716 | <1% | 3,243 | $0.01 | |
| 90656 | <1% | 177 | $0.01 | |
| 90707 | <1% | 3,251 | $0.01 | |
| 90670 | <1% | 5,507 | $0.01 | |
| 90715 | <1% | 1,304 | $0.01 | |
| 90696 | 0% | 1,439 | $0.00 | |
| 90723 | 0% | 5,142 | $0.00 | |
| 96127 | 0% | 591 | $0.00 | |
| 90680 | 0% | 3,872 | $0.00 | |
| 90651 | 0% | 1,626 | $0.00 | |
| 90744 | 0% | 12 | $0.00 | |
| 90381 | 0% | 18 | $0.00 | |
| 90688 | 0% | 40 | $0.00 | |
| 99173 | 0% | 2,778 | $0.00 | |
| 90734 | 0% | 1,936 | $0.00 | |
| 90700 | 0% | 1,649 | $0.00 | |
| 99177 | 0% | 4,326 | $0.00 | |
| 90633 | 0% | 3,480 | $0.00 | |
| 90681 | 0% | 609 | $0.00 | |
| 90648 | 0% | 6,859 | $0.00 | |
| 90710 | 0% | 62 | $0.00 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 59 | $0.00 |
| 90672 | 0% | 44 | $0.00 | |
| 90713 | 0% | 12 | $0.00 | |
| 90380 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAROUSE, AYMAN (PEDIATRICIAN)